Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.86 USD

28.86
12,948,956

-0.23 (-0.79%)

Updated Sep 30, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

by Zacks Equity Research

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance

by Zacks Equity Research

The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision in the U.S. is expected in 2023, while the decision in the EU is expected in 2024.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $51.66 in the latest trading session, marking a +0.66% move from the prior day.

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

by Zacks Equity Research

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Berkshire Hathaway, Exxon Mobil, Pfizer, Charles Schwab and ABB

by Zacks Equity Research

Berkshire Hathaway, Exxon Mobil, Pfizer, Charles Schwab and ABB are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Berkshire Hathaway, Exxon Mobil & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BR.B), Exxon Mobil Corporation (XOM) and Pfizer Inc. (PFE).

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

by Zacks Equity Research

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

by Zacks Equity Research

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion

by Zacks Equity Research

Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

by Zacks Equity Research

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates

by Kinjel Shah

A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.

Zacks Market Edge Highlights: LLY, PFE, JPM, ULTA, QQQ

by Zacks Equity Research

LLY, PFE, JPM, ULTA, QQQ have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Will There be a Recession in 2023?

by Tracey Ryniec

Tracey Ryniec and John Blank are back with their annual look at the economy and how to invest in the new year.

GSK & Others Get Relief as US Court Dismisses Zantac Litigation

by Zacks Equity Research

A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).

Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag

by Zacks Equity Research

The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.

Is Pfizer (PFE) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Pfizer (PFE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

by Zacks Equity Research

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab

by Zacks Equity Research

Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.

Shaun Pruitt headshot

Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?

by Shaun Pruitt

Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.

Derek Lewis headshot

Relative Strength Found Within These 3 Medical Stocks

by Derek Lewis

The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.